• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks Hitting New 52-Week Lows Today

    1/3/22 1:35:03 PM ET
    $AGIL
    $AGMH
    $ALVR
    $ANNX
    Professional Services
    Consumer Discretionary
    EDP Services
    Technology
    Get the next $AGIL alert in real time by email

     

     

    On Monday morning, 60 companies achieved new lows for the year.

    Points of Interest From Today's 52-Week Lows And Highs:

    • Ginkgo Bioworks Holdings (NYSE:DNA) was the largest firm on a market cap basis to set a new 52-week low.
    • Palisade Bio (NASDAQ:PALI) is the smallest company on a market cap basis to set a new 52-week low.
    • Applied Therapeutics (NASDAQ:APLT)'s stock moved significantly downwards, trading down 29.61% to reach a new 52-week low.
    • Nerdy (NYSE:NRDY) shares actually gained 0.0%, rebounding after it reached its 52-week low.

    These stocks set new 52-week lows during the first half-hour of trading on Monday:

    • Ginkgo Bioworks Holdings (NYSE:DNA) stock hit a new 52-week low of $7.95. The stock was up 2.65% on the session.
    • NovoCure (NASDAQ:NVCR) shares were up 6.53% for the day, having made a 52-week low of $74.67.
    • Natura &Co Holding (NYSE:NTCO) shares hit a yearly low of $8.71. The stock was down 2.1% on the session.
    • Olo (NYSE:OLO) shares set a new 52-week low of $20.09. The stock traded up 0.65%.
    • Sana Biotechnology (NASDAQ:SANA) stock achieved a new 52-week low on Monday morning, hitting $14.83 and moving up 0.12%.
    • Vertex (NASDAQ:VERX) shares reached a new 52-week low of $15.60 on Monday morning, moving up 4.3%.
    • Editas Medicine (NASDAQ:EDIT) shares were up 3.73% for the day, having made a 52-week low of $25.91.
    • Sorrento Therapeutics (NASDAQ:SRNE) stock set a new 52-week low of $4.57 on Monday, moving up 4.19%.
    • Inovio Pharmaceuticals (NASDAQ:INO) shares were up 2.91% for the day, having made a 52-week low of $4.92.
    • Burning Rock Biotech (NASDAQ:BNR) stock achieved a new 52-week low on Monday morning, hitting $9.16 and moving up 3.54%.
    • Companhia Brasileira (NYSE:CBD) shares reached a new 52-week low of $3.70 on Monday morning, moving down 6.77%.
    • AlloVir (NASDAQ:ALVR) shares set a new yearly low of $12.57 this morning. The stock was up 2.7% on the session.
    • Humacyte (NASDAQ:HUMA) shares moved up 1.24% on Monday to hit a new 52-week low of $7.02, drifting up 1.24%.
    • Dyne Therapeutics (NASDAQ:DYN) shares moved up 1.56% on Monday to hit a new 52-week low of $11.51, drifting up 1.56%.
    • BlackSky Technology (NYSE:BKSY) stock hit $4.34 on Monday morning, setting a new 52-week low for a change of up 2.0%.
    • Annexon (NASDAQ:ANNX) shares set a new yearly low of $11.05 this morning. The stock was up 1.48% on the session.
    • Taysha Gene Therapies (NASDAQ:TSHA) shares hit a yearly low of $11.09. The stock was down 0.86% on the session.
    • Cleanspark (NASDAQ:CLSK) shares reached a new 52-week low of $9.43 on Monday morning, moving up 3.15%.
    • AppHarvest (NASDAQ:APPH) shares moved up 1.67% on Monday to hit a new 52-week low of $3.75, drifting up 1.67%.
    • Nerdy (NYSE:NRDY) stock dropped to a yearly low on Monday of $4.33. Shares traded 0.0% (flat).
    • Blackrock Income Trust (NYSE:BKT) shares set a new 52-week low of $5.61. The stock traded down 0.55%.
    • Passage Bio (NASDAQ:PASG) shares were up 1.1% for the day, having made a 52-week low of $6.12.
    • Newcourt Acquisition (NASDAQ:NCAC) shares were down 0.2% for the day, having made a 52-week low of $9.87.
    • Momentus (NASDAQ:MNTS) shares set a new yearly low of $4.06 this morning. The stock was up 2.39% on the session.
    • VPC Impact Acquisition (NYSE:VPCC) shares moved down 5.76% on Monday to hit a new 52-week low of $9.50, drifting down 5.76%.
    • P3 Health Partners (NASDAQ:PIII) shares made a new 52-week low of $6.52 on Monday. The stock was down 4.26% for the day.
    • Zenvia (NASDAQ:ZENV) shares reached a new 52-week low of $6.51 on Monday morning, moving up 2.65%.
    • Humanigen (NASDAQ:HGEN) stock drifted up 0.13% on Monday morning to hit a new 52-week low of $3.56.
    • AgileThought (NASDAQ:AGIL) shares set a new yearly low of $4.61 this morning. The stock was up 2.29% on the session.
    • WAVE Life Sciences (NASDAQ:WVE) shares set a new 52-week low of $3.02. The stock traded up 0.96%.
    • VirnetX Holding (NYSE:VHC) shares reached a new 52-week low of $2.53 on Monday morning, moving down 0.38%.
    • Applied Therapeutics (NASDAQ:APLT) shares set a new 52-week low of $6.00. The stock traded down 29.61%.
    • Platinum Group Metals (AMEX:PLG) shares hit a yearly low of $1.55. The stock was up 5.38% on the session.
    • Tyme Technologies (NASDAQ:TYME) stock dropped to a yearly low on Monday of $0.60. Shares traded up 4.13%.
    • Waitr Hldgs (NASDAQ:WTRH) stock hit $0.73 on Monday morning, setting a new 52-week low for a change of up 1.23%.
    • GT Biopharma (NASDAQ:GTBP) stock achieved a new 52-week low on Monday morning, hitting $2.89 and moving up 1.31%.
    • Ocean Power Technologies (AMEX:OPTT) shares hit a yearly low of $1.47. The stock was up 6.08% on the session.
    • HCW Biologics (NASDAQ:HCWB) shares reached a new 52-week low of $2.30 on Monday morning, moving up 0.72%.
    • IN8bio (NASDAQ:INAB) shares set a new yearly low of $4.19 this morning. The stock was down 4.43% on the session.
    • Nova Vision Acquisition (NASDAQ:NOVV) stock hit a new 52-week low of $9.86. The stock was up 0.2% on the session.
    • HOOKIPA Pharma (NASDAQ:HOOK) stock hit a yearly low of $2.28. The stock was 0.0% (flat) for the day.
    • Clarus Therapeutics Hldgs (NASDAQ:CRXT) stock hit a yearly low of $2.32. The stock was down 3.29% for the day.
    • AGM Gr Hldgs (NASDAQ:AGMH) shares set a new 52-week low of $2.30. The stock traded up 3.33%.
    • Xtant Medical Holdings (AMEX:XTNT) shares moved up 1.09% on Monday to hit a new 52-week low of $0.55, drifting up 1.09%.
    • Regulus Therapeutics (NASDAQ:RGLS) shares hit a yearly low of $0.31. The stock was up 0.67% on the session.
    • Fangdd Network Group (NASDAQ:DUO) stock hit a new 52-week low of $0.40. The stock was down 1.1% on the session.
    • Bright Minds Biosciences (NASDAQ:DRUG) shares set a new yearly low of $3.07 this morning. The stock was down 2.84% on the session.
    • Vaccinex (NASDAQ:VCNX) shares hit a yearly low of $1.02. The stock was up 8.65% on the session.
    • Soligenix (NASDAQ:SNGX) shares were up 4.5% for the day, having made a 52-week low of $0.66.
    • IDW Media Holdings (AMEX:IDW) shares reached a new 52-week low of $1.86 on Monday morning, moving down 7.0%.
    • Palisade Bio (NASDAQ:PALI) stock hit $1.26 on Monday morning, setting a new 52-week low for a change of up 6.15%.
    •  

    Be sure to monitor Benzinga for the news traders need! And for even more up-to-date info on 52-week lows and highs, check out Benzinga Pro. This cutting-edge market research platform alerts traders of which stocks are trading near their 52-week highs and lows each morning - and delivers lots of other actionable data. Learn more here.

    Get the next $AGIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGIL
    $AGMH
    $ALVR
    $ANNX

    CompanyDatePrice TargetRatingAnalyst
    Wave Life Sciences Ltd.
    $WVE
    2/5/2026$38.00Buy
    BofA Securities
    Vertex Inc.
    $VERX
    2/3/2026$20.00Overweight → Neutral
    Piper Sandler
    CleanSpark Inc.
    $CLSK
    1/13/2026$22.50Outperform
    Northland Capital
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    CleanSpark Inc.
    $CLSK
    1/8/2026$22.00Buy
    Maxim Group
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Annexon Inc.
    $ANNX
    12/23/2025$16.00Buy
    Chardan Capital Markets
    BlackSky Technology Inc.
    $BKSY
    12/22/2025$23.00Buy
    Jefferies
    More analyst ratings

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CHIEF FINANCIAL OFFICER Mccall Patrick

    4 - IN8BIO, INC. (0001740279) (Issuer)

    2/6/26 4:30:26 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by President and COO Rochlin Kate

    4 - IN8BIO, INC. (0001740279) (Issuer)

    2/6/26 4:30:23 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by EVP and CSO Lamb Lawrence

    4 - IN8BIO, INC. (0001740279) (Issuer)

    2/6/26 4:30:27 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    SEC Filings

    View All

    SEC Form 424B5 filed by Momentus Inc.

    424B5 - Momentus Inc. (0001781162) (Filer)

    2/6/26 4:53:27 PM ET
    $MNTS
    Military/Government/Technical
    Industrials

    SEC Form S-8 filed by Ocean Power Technologies Inc.

    S-8 - Ocean Power Technologies, Inc. (0001378140) (Filer)

    2/6/26 4:18:33 PM ET
    $OPTT
    Electric Utilities: Central
    Utilities

    Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.

    SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

    2/6/26 3:00:09 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Carson William H. bought $20,657 worth of shares (4,115 units at $5.02), increasing direct ownership by 8% to 54,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    1/2/26 4:30:06 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Wave Life Sciences with a new price target

    BofA Securities initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $38.00

    2/5/26 9:31:24 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Vertex from Overweight to Neutral and set a new price target of $20.00

    2/3/26 6:54:33 AM ET
    $VERX
    Computer Software: Prepackaged Software
    Technology

    Northland Capital initiated coverage on CleanSpark with a new price target

    Northland Capital initiated coverage of CleanSpark with a rating of Outperform and set a new price target of $22.50

    1/13/26 10:12:54 AM ET
    $CLSK
    Finance: Consumer Services
    Finance

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    DALLAS, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on February 2, 2026, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, restricted stock units (RSUs) representing 349,000 shares of the Company's common stock in connection with their employment. The RSUs were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering empl

    2/6/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CleanSpark Delivers $181 Million in Q1 Revenue, Strengthens Balance Sheet, and Advances Multi-Gigawatt AI Infrastructure Platform

    Secures up to 890 MW of New Utility-Grade Power Capacity and Expands AI-Ready Site Portfolio Across Texas and Georgia LAS VEGAS, Feb. 5, 2026 /PRNewswire/ -- CleanSpark, Inc. (NASDAQ:CLSK) ("CleanSpark" or the "Company"), today reported financial results for the quarter ended December 31, 2025. "CleanSpark exited the quarter with one of the strongest balance sheets in our sector and a power and land portfolio that is increasingly scarce," said Matt Schultz, CleanSpark's CEO and Chairman. "We strengthened our financial foundation, secured up to 890 megawatts of high-quality uti

    2/5/26 4:05:00 PM ET
    $CLSK
    Finance: Consumer Services
    Finance

    Nerdy to Announce Fourth Quarter and Full Year 2025 Results on February 26, 2026

    Nerdy Inc. (NYSE:NRDY), a leading platform for delivering live online learning, today announced the Company will release its fourth quarter and full year financial results for the period ended December 31, 2025 after the U.S. stock market closes on Thursday, February 26, 2026. Following the release, Nerdy management will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial and operating results. Interested parties in the U.S. may listen to the call by dialing 1-833-470-1428. International callers can dial 1-404-975-4839. The Access Code is 541162. A live webcast of the call will also be available on Nerdy's investor relations website at https://w

    2/5/26 4:01:00 PM ET
    $NRDY
    Other Consumer Services
    Real Estate

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    Leadership Updates

    Live Leadership Updates

    View All

    Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors

    BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, effective January 1, 2026. Dr. Incerti is a highly accomplished executive with a strong background in medicine and over 35 years of strategic experience in the biopharmaceutical industry. "Carlo's appointment comes at a pivotal moment for Sparrow as we are looking ahead to pivotal trials of clofutriben for type 2 diabetes and seeking to expand development into other cardiometabolic indications," said Robert Jacks, Sparrow President and Chief Executive Officer. "Carlo is respected globally for

    2/2/26 8:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morning Market Pulse: AI, Autonomy, and National Security Drive the Narrative at the Open

    DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Markets are waking up to a distinctly forward-looking tape, with investors parsing developments that point to shifts in Artificial Intelligence infrastructure, advanced sensing, defense-aligned energy systems, and deep-tech R&D platforms. Envirotech Vehicles (NASDAQ:EVTV): Strategic Pivot Toward AI Infrastructure Envirotech Vehicles is in focus after announcing an amended and restated Letter of Intent to acquire AZIO AI Corporation, a move that could dramatically reshape the company's long-term identity. The proposed all-equity transaction values AZIO AI at an assumed enterprise value of $480 million, using a $3.00 per share reference price for E

    1/6/26 9:52:32 AM ET
    $AEVA
    $EVTV
    $OPTT
    Auto Parts:O.E.M.
    Consumer Discretionary
    Electric Utilities: Central
    Utilities

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    Financials

    Live finance-specific insights

    View All

    CleanSpark Delivers $181 Million in Q1 Revenue, Strengthens Balance Sheet, and Advances Multi-Gigawatt AI Infrastructure Platform

    Secures up to 890 MW of New Utility-Grade Power Capacity and Expands AI-Ready Site Portfolio Across Texas and Georgia LAS VEGAS, Feb. 5, 2026 /PRNewswire/ -- CleanSpark, Inc. (NASDAQ:CLSK) ("CleanSpark" or the "Company"), today reported financial results for the quarter ended December 31, 2025. "CleanSpark exited the quarter with one of the strongest balance sheets in our sector and a power and land portfolio that is increasingly scarce," said Matt Schultz, CleanSpark's CEO and Chairman. "We strengthened our financial foundation, secured up to 890 megawatts of high-quality uti

    2/5/26 4:05:00 PM ET
    $CLSK
    Finance: Consumer Services
    Finance

    Nerdy to Announce Fourth Quarter and Full Year 2025 Results on February 26, 2026

    Nerdy Inc. (NYSE:NRDY), a leading platform for delivering live online learning, today announced the Company will release its fourth quarter and full year financial results for the period ended December 31, 2025 after the U.S. stock market closes on Thursday, February 26, 2026. Following the release, Nerdy management will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial and operating results. Interested parties in the U.S. may listen to the call by dialing 1-833-470-1428. International callers can dial 1-404-975-4839. The Access Code is 541162. A live webcast of the call will also be available on Nerdy's investor relations website at https://w

    2/5/26 4:01:00 PM ET
    $NRDY
    Other Consumer Services
    Real Estate

    BlackSky to Host Fourth Quarter and Full Year 2025 Results Conference Call

    BlackSky Technology Inc. (NYSE: BKSY) will host a live webcast and conference call to discuss fourth quarter and full year 2025 financial results and its business outlook on Thursday, February 26, 2026, at 8:30 a.m. EST. A press release with BlackSky's financial results will be released in advance of the conference call that same day. To access the live webcast, please click here or visit the company's investor relations website at http://ir.blacksky.com and then select "News & Events". To eliminate wait times, conference call participants may pre-register here. After registering, a confirmation with access details will be sent via email. The webcast and conference call will be archived o

    2/5/26 7:00:00 AM ET
    $BKSY
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fangdd Network Group Ltd.

    SC 13G - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:26:40 PM ET
    $DUO
    Real Estate
    Finance

    Amendment: SEC Form SC 13G/A filed by Fangdd Network Group Ltd.

    SC 13G/A - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:24:27 PM ET
    $DUO
    Real Estate
    Finance

    Amendment: SEC Form SC 13D/A filed by Nerdy Inc.

    SC 13D/A - Nerdy Inc. (0001819404) (Subject)

    12/4/24 4:01:10 PM ET
    $NRDY
    Other Consumer Services
    Real Estate